Cholesterol in human atherosclerotic plaque is a marker for underlying disease state and plaque vulnerability
© Chen et al; licensee BioMed Central Ltd. 2010
Received: 28 April 2010
Accepted: 11 June 2010
Published: 11 June 2010
Cholesterol deposition in arterial wall drives atherosclerosis. The key goal of this study was to examine the relationship between plaque cholesterol content and patient characteristics that typically associate with disease state and lesion vulnerability. Quantitative assays for free cholesterol, cholesteryl ester, triglyceride, and protein markers in atherosclerotic plaque were established and applied to plaque samples from multiple patients and arterial beds (Carotid and peripheral arteries; 98 lesions in total).
We observed a lower cholesterol level in restenotic than primary peripheral plaque. We observed a trend toward a higher level in symptomatic than asymptomatic carotid plaque. Peripheral plaque from a group of well-managed diabetic patients displayed a weak trend of more free cholesterol deposition than plaque from non-diabetic patients. Plaque triglyceride content exhibited less difference in the same comparisons. We also measured cholesterol in multiple segments within one carotid plaque sample, and found that cholesterol content positively correlated with markers of plaque vulnerability, and negatively correlated with stability markers.
Our results offer important biological validation of cholesterol as a key lipid marker for plaque severity. Results also suggest cholesterol is a more sensitive plaque marker than routine histological staining for neutral lipids.
Atherosclerosis is a chronic disease characterized by lipid deposition and inflammation in the arterial wall. Cholesterol is the major lipid species in atherosclerotic lesions and accumulates in both unesterified and esterified forms. Early studies characterizing localization and abundance of cholesterol in association with lesion morphology and severity have illuminated the prominent role of cholesterol in athero-progression. Rapp et al. observed that an increased percentage of free cholesterol (as a proportion of total cholesterol) was associated with evolution of the atherosclerotic process. Kruth further demonstrated that free and esterified cholesterol accumulated within many diverse and distinct structures in lesions, and extracellular free cholesterol-enriched particles constituted a significant portion of accumulated cholesterol. Klemp et al. found that lesion cores showed an increase in the percentage of free cholesterol, whereas lesion caps were more enriched in cholesteryl ester. These studies in aggregate suggest that deposition of free and esterified cholesterol has a critical physiological impact on athero-progression.
A large body of evidence supporting cholesterol's central role in atherosclerosis was generated using histochemical analysis with lipid-soluble Sudan dyes such as Oil Red O (ORO). These dyes stain neutral lipids including cholesteryl ester and triglyceride, but they do not stain free cholesterol. Nonetheless, such stains in human plaque have demonstrated that lipid enrichment is usually associated with higher degrees of inflammation and characteristics of plaque vulnerability.
In addition to being a key driver for atherosclerosis, cholesterol is dynamically modulated in lesion regression or stabilization. A robust reduction in free and esterified cholesterol in response to treatment with certain agents has been observed in animal studies[8–10]. In clinical studies, although quantitation of lesion cholesterol has not been utilized as study outcome, histological analyses have demonstrated that certain therapies, such as statins, can result in reduction in lipid-rich region in lesions.
In our effort of using plaque as a quantitative platform for studying effect of novel therapeutic entities in humans, we sought to explore the relationship between plaque cholesterol content and patient characteristics that have been implicated in lesion pathogenesis. We analyzed free and esterified cholesterol levels, along with other lipid and protein markers, in lesions from three stratified patient cohorts. Correlations between cholesterol levels and patient characteristics constitute key results in this report. We also provide an analysis of cholesterol content in different segments within one plaque as additional validation of our approach.
Human atherosclerotic lesions
Patient Characteristics of the Diabetic (DM) and Non-diabetic (non-DM) Groups
Male gender (total)
Total Cholesterol, mg/dL
Protein extraction and measurement
RNAlater-stored plaques were removed from RNAlater and powderized by TissueLyser (Qiagen) at -80°C before processing for protein. Flash frozen plaques were pulverized by Covaris Tissue CryoPrep system (Covaris, Inc.) at -80°C before processing for protein. Tissue slices from the OCT-embedded carotid plaque were also pulverized. Protein in the pulverized or powderized samples were extracted with PBS + 1%CHAPS in the Covaris E210 tissue extraction system and stored at -80°C until assay. Pellets were stored at -80°C until processing for lipids. CD68 was measured using an immunoassay developed for human CD68. The calibrator for the assay was a lysate of the macrophage cell line THP-1, hence the results of CD68 measurement are expressed as μg of THP-1 lysate. ICAM-1 levels were determined by Rules Based Medicine Human MAP multi-analyte analysis. Lumican and Smooth Muscle Myosin Heavy Chain (SMMHC) levels were determined by Western blotting, with the goat anti-Lumican (R&D Systems) and mouse anti-SMMHC (Dako) used as primary antibodies. Cathepsin B was measured by an immunoassay from R&D Systems.
Lipid extraction and measurement
Pellets resulted from protein extraction were subjected to lipid extraction by the Folch method. For cholesterol measurement, lipid extracts were spotted onto 96-well plates, dried, and resolubilized in ethanol. To measure free cholesterol, samples were incubated for 1 hour at 37°C in a reaction mixture that includes cholesterol oxidase, peroxidase, and p-hydroxyphenylacetic acid, with the fluorescent product measured in a Tecan GENios Pro. Cholesterol esterase (Calbiochem) was included in separate reactions for measuring total cholesterol. Cholesteryl ester content was derived by subtracting free cholesterol from total cholesterol. For triglyceride measurement, lipid extracts were spotted onto 96-well plates, dried, and resolubilized in 4% Triton X-100. Triglyceride assay reagent (Roche) was then added to each well to allow reaction at room temperature for 10 minutes, with the colorimetric product measured in a Spectra Max 250 (Molecular Devices).
Histology and immunohistochemistry
10 μm tissue sections were generated from the OCT-embedded plaque by Cryostat. Hemotoxylin & eosin (H&E) staining was performed by routine methods. Mouse anti-CD68 (Neomarkers, Ab-3) and mouse anti-SMMHC (Neomarkers, SMMS-1) were used for immunohistochemistry for CD68 and SMMHC, respectively.
For all whole plaque samples, the analytes' values were normalized to tissue weight. Cholesterol and triglyceride were expressed as nmol/mg tissue, and Lumican was expressed in units of AU (arbitrary unit) per mg tissue. For the OCT-embedded plaque slices, the analytes' values were normalized to total protein. Cholesterol and triglyceride were expressed as nmol/mg protein; ICAM-1, CD68, SMMHC were expressed as ng/mg protein, μg THP-1/mg protein, and AU/mg protein, respectively. T-tests were generated using Microsoft Excel's functions. For comparison between patient groups, natural logarithm transformation was applied to the normalized analytes' levels to meet the normality assumption for statistical analyses.
Restenotic plaque had lower cholesterol content than primary plaque
Since it is known that restenotic plaque has proteoglycan-enriched extracellular matrix, we were curious about a small soluble proteoglycan, Lumican, in this study. Lumican was previously characterized as dynamically present in various stages of lesion progression and potentially involved in smooth muscle proliferation[17, 18]. Our analysis revealed Lumican was highly abundant in plaque samples, with its SDS-PAGE migration pattern similar to previously observed (Fig. 1G); restenotic lesions had significantly more Lumican than primary lesions (Fig. 1H), suggesting that Lumican may indeed be involved in the smooth muscle cell proliferation process underlying restenosis.
Symptomatic carotid plaque trended toward more cholesterol deposition than asymptomatic plaque
Cholesterol content in diabetic vs. non-diabetic peripheral plaques
Cholesterol analysis in multiple segments within one carotid plaque
Cholesterol content in carotid plaque vs. peripheral plaque
In this report we made novel observations about human plaque regarding the relationship between plaque cholesterol content and a number of clinical parameters that typically associate with plaque instability. Our findings confirmed and extended the established understanding on free and esterified cholesterol in plaque, validated our approach, and solidified our understanding of atherosclerosis.
In interpreting our results we need to keep in mind that histopathological features of plaque are modifiable by multiple additional clinical parameters and risk factors. For example, a large carotid plaque study by Rothwell and colleagues showed that key lesion characteristics are highly influenced by nature and timing of ischemic events, and relationship between lesion characteristics and diabetes displayed a temporal trend as well. Histological features of restenotic plaque are also highly dynamic and dependent on recurrence interval and clinical presentation, with late restenotic lesion starting to resemble primary lesion. It is therefore unsurprising that sample sizes for such binary comparisons are usually too small and results need to be taken with recognition of caveats with such a validation approach. Nonetheless, our observations are consistent with a larger body of literature on plaque inflammation and lipid deposition in relation to neurological symptoms, diabetes, and restenosis.
Our observation that carotid plaques had significantly more TC and higher percentage of FC than peripheral plaques is consistent with previous findings that carotid arteries have a higher prevalence of foam cell lesions and lipid core plaques than peripheral arteries. Our intra-plaque analysis of cholesterol content in comparison with protein markers is also consistent with the understanding of role of cholesterol in plaque vulnerability.
Our specific analyses of FC and CE in the symptomatic/asymptomatic comparison and DM/non-DM comparison suggest FC is a more sensitive marker of plaque severity than CE. From the perspective of drug effect, in animal studies, reduction in CE by therapeutic entities appeared to always exceed reduction in FC[8–10]. Although such comparisons in human lesions are yet to be reported, it is plausible that we will observe the same pattern in human drug trials. Main reason for this expectation is that we believe the predominant mechanism of cholesterol reduction in lesion is cholesterol efflux from CE-enriched cells and a high percentage of FC in advanced human lesions exists in the extracellular space in inaccessible forms. Distinguishing CE from FC is therefore a highly desirable capability of our platform. Animal studies also suggested reduction in CE by drug treatment could exceed reduction in triglyceride. Since both CE and triglyceride stain positive with ORO, our results together with available literature evidence suggest specific quantitation of FC and CE may allow us better sensitivity in gauging plaque severity and drug effect than neutral lipids staining with ORO.
Our cholesterol analyses across different arterial beds and patient groups have also added a value to our platform-building effort in that they provided a new dimension in assessing protein and RNA biomarkers. Indeed, through plaque splitting, which allows parallel measurement of cholesterol, protein, and RNA markers within one tissue sample (manuscript submitted), we have identified a host of protein markers and gene expression signatures that correlate with cholesterol deposition (not shown). Further analysis of these findings will not only validate our approach but also yield new insight on the complex plaque biology. Our lipid extraction and cholesterol measurements also opened the door to establishing and evaluating additional plaque lipid components that are potentially implicated in lesion progression. Finally, our results could also serve as an important benchmark for assessing various newly-emerged imaging modalities that bear the promise of quantitating lipid content in plaque.
We have integrated cholesterol measurement into our human plaque analysis as a potential platform for reading drug effect. Our studies, to our best knowledge, mark the first effort of correlating plaque cholesterol content, including free and esterified cholesterol, with multiple patient characteristics. Our findings demonstrate that specific and quantitative analysis of cholesterol serves as an excellent marker for plaque vulnerability and potentially a very suitable endpoint for measuring drug effect. Clinical studies in which we will measure a comprehensive endpoint that includes plaque cholesterol, protein, RNA, and imaging parameters in response to drug treatment are under way. Results also support the notion that deposition of cholesterol, in particular free cholesterol, in human atherosclerotic plaque, is a marker for underlying disease state and lesion progression.
We thank Cheryl Le Grand, Jiyan Xue, and Gloria Lazar for their technical assistance in processing plaque samples; we thank Jeff Yuan, Vladimir Reiser, and Edward O'Neill for discussions. All studies were funded by Merck Research Laboratories.
- Libby P: Inflammation in atherosclerosis. Nature. 2002, 420: 868-74. 10.1038/nature01323View ArticlePubMedGoogle Scholar
- Insull W, Bartsch GE: Cholesterol, triglyceride, and phospholipid content of intima, media, and atherosclerotic fatty streak in human thoracic aorta. J Clin Invest. 1966, 45: 513-23. 10.1172/JCI105365PubMed CentralView ArticlePubMedGoogle Scholar
- Rapp JH, Connor WE, Lin DS, Inahara T, Porter JM: Lipids of human atherosclerotic plaques and xanthomas: clues to the mechanism of plaque progression. J Lipid Res. 1983, 24: 1329-35.PubMedGoogle Scholar
- Kruth HS: Localization of unesterified cholesterol in human atherosclerotic lesions. Demonstration of filipin-positive, oil-red-O-negative particles. Am J Pathol. 1984, 114: 201-8.PubMed CentralPubMedGoogle Scholar
- Guyton JR, Klemp KF: Development of the atherosclerotic core region. Chemical and ultrastructural analysis of microdissected atherosclerotic lesions from human aorta. Arterioscler Thromb. 1994, 14: 1305-14.View ArticlePubMedGoogle Scholar
- van Gent CM, Emeis JJ: Histochemistry of free and esterified cholesterol in human atherosclerotic arteries. Prog Biochem Pharmacol. 1977, 13: 262-7.PubMedGoogle Scholar
- Verhoeven B, Hellings WE, Moll FL, de Vries JP, de Kleijn DP, de Bruin P, Busser E, Schoneveld AH, Pasterkamp G: Carotid atherosclerotic plaques in patients with transient ischemic attacks and stroke have unstable characteristics compared with plaques in asymptomatic and amaurosis fugax patients. J Vasc Surg. 2005, 42: 1075-81. 10.1016/j.jvs.2005.08.009View ArticlePubMedGoogle Scholar
- Badimon JJ, Badimon L, Fuster V: Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990, 85: 1234-41. 10.1172/JCI114558PubMed CentralView ArticlePubMedGoogle Scholar
- Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatkab A, Wang PR, Zhang D, Peterson L, Detmers PA, Chao YS, Wright SD: Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 2001, 21: 115-21.View ArticlePubMedGoogle Scholar
- Morehouse LA, Sugarman ED, Bourassa PA, Sand TM, Zimetti F, Gao F, Rothblat GH, Milici AJ: Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res. 2007, 48: 1263-72. 10.1194/jlr.M600332-JLR200View ArticlePubMedGoogle Scholar
- Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001, 103: 926-33.View ArticlePubMedGoogle Scholar
- Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957, 226: 497-509.PubMedGoogle Scholar
- Skowasch D, Jabs A, Andrie R, Dinkelbach S, Schiele TM, Wernert N, Luderitz B, Bauriedel G: Pathogen burden, inflammation, proliferation and apoptosis in human in-stent restenosis. Tissue characteristics compared to primary atherosclerosis. J Vasc Res. 2004, 41: 525-34. 10.1159/000081809View ArticlePubMedGoogle Scholar
- Hellings WE, Moll FL, de Vries JP, de Bruin P, de Kleijn DP, Pasterkamp G: Histological characterization of restenotic carotid plaques in relation to recurrence interval and clinical presentation: a cohort study. Stroke. 2008, 39: 1029-32. 10.1161/STROKEAHA.107.496703View ArticlePubMedGoogle Scholar
- Papaspyridonos M, Smith A, Burnand KG, Taylor P, Padayachee S, Suckling KE, James CH, Greaves DR, Patel L: Novel candidate genes in unstable areas of human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2006, 26: 1837-44. 10.1161/01.ATV.0000229695.68416.76View ArticlePubMedGoogle Scholar
- Matsuura R, Isaka N, Imanaka-Yoshida K, Yoshida T, Sakakura T, Nakano T: Deposition of PG-M/versican is a major cause of human coronary restenosis after percutaneous transluminal coronary angioplasty. J Pathol. 1996, 180: 311-6. 10.1002/(SICI)1096-9896(199611)180:3<311::AID-PATH657>3.0.CO;2-BView ArticlePubMedGoogle Scholar
- Talusan P, Bedri S, Yang S, Kattapuram T, Silva N, Roughley PJ, Stone JR: Analysis of intimal proteoglycans in atherosclerosis-prone and atherosclerosis-resistant human arteries by mass spectrometry. Mol Cell Proteomics. 2005, 4: 1350-7. 10.1074/mcp.M500088-MCP200PubMed CentralView ArticlePubMedGoogle Scholar
- Onda M, Ishiwata T, Kawahara K, Wang R, Naito Z, Sugisaki Y: Expression of lumican in thickened intima and smooth muscle cells in human coronary atherosclerosis. Exp Mol Pathol. 2002, 72: 142-9. 10.1006/exmp.2002.2425View ArticlePubMedGoogle Scholar
- Razani B, Chakravarthy MV, Semenkovich CF: Insulin resistance and atherosclerosis. Endocrinol Metab Clin North Am. 2008, 37: 603-21. 10.1016/j.ecl.2008.05.001PubMed CentralView ArticlePubMedGoogle Scholar
- Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, Fallon JT: Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation. 2000, 102: 2180-4.View ArticlePubMedGoogle Scholar
- Marfella R, D'Amico M, Esposito K, Baldi A, Di Filippo C, Siniscalchi M, Sasso FC, Portoghese M, Cirillo F, Cacciapuoti F, Carbonara O, Crescenzi B, Baldi F, Ceriello A, Nicoletti GF, D'Andrea F, Verza M, Coppola L, Rossi F, Giugliano D: The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes. 2006, 55: 622-32. 10.2337/diabetes.55.03.06.db05-0832View ArticlePubMedGoogle Scholar
- Redgrave JN, Lovett JK, Gallagher PJ, Rothwell PM: Histological assessment of 526 symptomatic carotid plaques in relation to the nature and timing of ischemic symptoms: the Oxford plaque study. Circulation. 2006, 113: 2320-8. 10.1161/CIRCULATIONAHA.105.589044View ArticlePubMedGoogle Scholar
- Redgrave JN, Lovett JK, Syed AB, Rothwell PM: Histological features of symptomatic carotid plaques in patients with impaired glucose tolerance and diabetes (oxford plaque study). Cerebrovasc Dis. 2008, 26: 79-86. 10.1159/000136900View ArticlePubMedGoogle Scholar
- Dalager S, Paaske WP, Kristensen IB, Laurberg JM, Falk E: Artery-related differences in atherosclerosis expression: implications for atherogenesis and dynamics in intima-media thickness. Stroke. 2007, 38: 2698-705. 10.1161/STROKEAHA.107.486480View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.